Niki BioSolutions, Inc.

Aptorum Group Limited is a clinical-stage biopharmaceutical enterprise focused on researching, developing, and commercializing novel therapeutic drug candidates and healthcare solutions. Its primary development pipeline centers on preclinical and clinical drug assets, including its lead projects ALS-4 and SACT-1, with SACT-1 targeted as a pediatric formulation for neuroblastoma. In addition to pharmaceutical drug candidates, the organization previously engaged in healthcare service operations through an outpatient medical clinic known as Talem Medical, serving individual clinical patients via employed physicians.

The company operates an in-house pharmaceutical development facility situated in the Hong Kong Science and Technology Park. Incorporated in the Cayman Islands, the organization maintains principal executive offices in London, United Kingdom, while conducting the substantial majority of its business and operational undertakings from Hong Kong. Its research, development, and regulatory activities span international jurisdictions, including engagements across the United States, Europe, and the People's Republic of China.

Summary of the business section of Niki BioSolutions's latest annual report, written by StockData.

“As of the date hereof, we have 2 full-time employees, one of whom is the Chief Executive Officer and the other who is engaged in general and administrative functions and who is located in Asia.”